NCT01183364 2014-09-19
A Dose Escalation Study of STA-9090 and Docetaxel in Patients With Solid Tumors
Synta Pharmaceuticals Corp.
Phase 1 Completed
Clinical Trials
5 trialsNCT00687934 2014-09-18
Study of STA-9090, Administered Once-Weekly in Patients With Solid Tumors
Synta Pharmaceuticals Corp.
Phase 1 Completed
NCT00688116 2014-09-18
Study of STA-9090, Administered Twice-Weekly in Patients With Solid Tumors
Synta Pharmaceuticals Corp.
Phase 1 Unknown
NCT00858572 2014-09-18
STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders
Synta Pharmaceuticals Corp.
Phase 1 Completed
NCT00964873 2014-09-18
A Phase 1 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous Leukemia
Synta Pharmaceuticals Corp.
Phase 1 Completed